{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:16:06Z","timestamp":1789690566197,"version":"4.0.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2011,6,26]],"date-time":"2011-06-26T00:00:00Z","timestamp":1309046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/s00105-011-2189-7","type":"journal-article","created":{"date-parts":[[2011,6,25]],"date-time":"2011-06-25T18:28:07Z","timestamp":1309026487000},"page":"852-858","source":"Crossref","is-referenced-by-count":12,"title":["Therapieresistentes Anti-Laminin-332-Schleimhautpemphigoid","Treatment-refractory anti-laminin\u00a0332 mucous membrane pemphigoid"],"prefix":"10.1007","volume":"62","author":[{"given":"A.","family":"Recke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Shimanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Steven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,26]]},"reference":[{"key":"2189_CR1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/archderm.138.3.370","volume":"138","author":"Chan","year":"2002","unstructured":"Chan LS, Ahmed AR, Anhalt GJ et al (2002) The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 138:370\u2013379","journal-title":"Arch Dermatol"},{"key":"2189_CR2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1523-1747.2001.01246.x","volume":"116","author":"Egan","year":"2001","unstructured":"Egan CA, Reddy D, Nie Z et al (2001) IgG anti-LABD97 antibodies in bullous pemphigoid patients\u2018 sera react with the mid-portion of the BPAg2 ectodomain. J Invest Dermatol 116:348\u2013350","journal-title":"J Invest Dermatol"},{"key":"2189_CR3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","volume":"6","author":"Hertl","year":"2008","unstructured":"Hertl M, Zillikens D, Borradori L et al (2008) Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 6:366\u2013373","journal-title":"J Dtsch Dermatol Ges"},{"key":"2189_CR4","doi-asserted-by":"crossref","unstructured":"Kasperkiewicz M, Shimanovich I, Ludwig RJ et al (2011) Rituximab for treatmentrefractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol [Epub ahead of print]","DOI":"10.1016\/j.jaad.2010.07.032"},{"key":"2189_CR5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/1523-1747.ep12323431","volume":"105","author":"Kirtschig","year":"1995","unstructured":"Kirtschig G, Marinkovich MP, Burgeson RE et al (1995) Anti-basement membrane autoantibodies in patients with anti-epiligrin cicatricial pemphigoid bind the alpha subunit of laminin 5. J Invest Dermatol 105:543\u2013548","journal-title":"J Invest Dermatol"},{"key":"2189_CR6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/archderm.138.3.380","volume":"138","author":"Kirtschig","year":"2002","unstructured":"Kirtschig G, Murrell D, Wojnarowska F et al (2002) Interventions for mucous membrane pemphigoid\/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol 138:380\u2013384","journal-title":"Arch Dermatol"},{"key":"2189_CR7","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1172\/JCI118942","volume":"98","author":"Lazarova","year":"1996","unstructured":"Lazarova Z, Yee C, Darling T et al (1996) Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest 98:1509\u20131518","journal-title":"J Clin Invest"},{"key":"2189_CR8","doi-asserted-by":"crossref","unstructured":"Le Roux-Villet C, Prost-Squarcioni C, Alexandre M et al (2011) Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol [Epub ahead of print]","DOI":"10.1001\/archdermatol.2011.54"},{"key":"2189_CR9","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/archderm.135.9.1091","volume":"135","author":"Leverkus","year":"1999","unstructured":"Leverkus M, Schmidt E, Lazarova Z et al (1999) Antiepiligrin cicatricial pemphigoid: an underdiagnosed entity within the spectrum of scarring auto immune subepidermal bullous diseases? Arch Dermatol 135:1091\u20131098","journal-title":"Arch Dermatol"},{"key":"2189_CR10","doi-asserted-by":"crossref","unstructured":"Lourari S, Herve C, Doffoel-Hantz V et al (2010) Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol [Epub ahead of print]","DOI":"10.1111\/j.1468-3083.2010.03889.x"},{"key":"2189_CR11","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1046\/j.1365-2133.2003.05513.x","volume":"149","author":"Luftl","year":"2003","unstructured":"Luftl M, Stauber A, Mainka A et al (2003) Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 149:598\u2013605","journal-title":"Br J Dermatol"},{"key":"2189_CR12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00347-008-1700-8","volume":"105","author":"Meyer-Ter-Vehn","year":"2008","unstructured":"Meyer-Ter-Vehn T, Schmidt E, Zillikens D et al (2008) Mucous membrane pemphigoid with ocular involvement. Part II: therapy. Ophthalmologe 105:405\u2013419","journal-title":"Ophthalmologe"},{"key":"2189_CR13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000187431","volume":"218","author":"Pfutze","year":"2009","unstructured":"Pfutze M, Eming R, Kneisel A et al (2009) Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology 218:237\u2013245","journal-title":"Dermatology"},{"key":"2189_CR14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ophtha.2007.04.027","volume":"115","author":"Saw","year":"2008","unstructured":"Saw VP, Dart JK, Rauz S et al (2008) Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology 115:253\u2013261","journal-title":"Ophthalmology"},{"key":"2189_CR15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1586\/17469872.3.3.259","volume":"3","author":"Schmidt","year":"2008","unstructured":"Schmidt E, Goebeler M (2008) CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab. Expert Rev Dermatol 3:259\u2013278","journal-title":"Expert Rev Dermatol"},{"key":"2189_CR16","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1046\/j.1365-2133.2003.05302.x","volume":"148","author":"Schmidt","year":"2003","unstructured":"Schmidt E, Klinker E, Opitz A et al (2003) Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 148:1222\u20131229","journal-title":"Br J Dermatol"},{"key":"2189_CR17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00347-008-1699-x","volume":"105","author":"Schmidt","year":"2008","unstructured":"Schmidt E, Meyer-Ter-Vehn T, Zillikens D et al (2008) Mucous membrane pemphigoid with ocular involvement. Part I: clinical manifestations, pathogenesis and diagnosis. Ophthalmologe 105:285\u2013297, quiz 298","journal-title":"Ophthalmologe"},{"key":"2189_CR18","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1046\/j.1365-2133.2001.04471.x","volume":"145","author":"Schmidt","year":"2001","unstructured":"Schmidt E, Skrobek C, Kromminga A et al (2001) Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol 145:778\u2013783","journal-title":"Br J Dermatol"},{"key":"2189_CR19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00403-009-1024-9","volume":"302","author":"Schmidt","year":"2010","unstructured":"Schmidt E, Zillikens D (2010) Immunoadsorption in dermatology. Arch Dermatol Res 302:241\u2013253","journal-title":"Arch Dermatol Res"},{"key":"2189_CR20","first-page":"296","volume":"7","author":"Schmidt","year":"2009","unstructured":"Schmidt E, Zillikens D (2009) Research in practice: diagnosis of subepidermal autoimmune bullous disorders. J Dtsch Dermatol Ges 7:296\u2013300","journal-title":"J Dtsch Dermatol Ges"},{"key":"2189_CR21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2133.2007.08358.x","volume":"158","author":"Shimanovich","year":"2008","unstructured":"Shimanovich I, Nitschke M, Rose C et al (2008) Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 158:382\u2013328","journal-title":"Br J Dermatol"},{"key":"2189_CR22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1610-0387.2007.06342.x","volume":"5","author":"Zillikens","year":"2007","unstructured":"Zillikens D, Derfler K, Eming R et al (2007) Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 5:881\u2013887","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-011-2189-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-011-2189-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-011-2189-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T09:29:37Z","timestamp":1560331777000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-011-2189-7"}},"subtitle":["Komplette Remission unter adjuvanter Immunapherese und Rituximab","Remission following adjuvant immunoadsorption and rituximab"],"short-title":[],"issued":{"date-parts":[[2011,6,26]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["2189"],"URL":"https:\/\/doi.org\/10.1007\/s00105-011-2189-7","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,26]]}}}